• argenx reported positive topline Phase 2 results for FB102 in celiac disease, supporting a move into Phase 3 development.
• Patients on FB102 showed reduced gluten-driven intestinal injury versus placebo during a controlled gluten challenge.
• Broad secondary measures aligned with the main outcome, including inflammation signals and patient-reported symptoms.
• No new safety concerns emerged; the safety profile matched prior studies.
• Detailed Phase 2 data will be presented at a future medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080100PRIMZONEFULLFEED1001276877) on October 08, 2026, and is solely responsible for the information contained therein.